TY - JOUR
T1 - Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients
T2 - A randomized double-blind placebo-controlled trial
AU - Turk, Suleyman
AU - Baki, Aysegul
AU - Solak, Yalcin
AU - Kayrak, Mehmet
AU - Atalay, Huseyin
AU - Gaipov, Abduzhappar
AU - Aribas, Alpay
AU - Akilli, Hakan
AU - Biyik, Zeynep
AU - Okudan, Nilsel
AU - Gokbel, Hakki
PY - 2013/7/1
Y1 - 2013/7/1
N2 - Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.
AB - Coenzyme Q10 (CoQ10) supplementation has been shown to improve diastolic heart function in various patient cohorts. Systolic and diastolic dysfunctions are common in patients with end-stage renal disease. Favorable effects of CoQ10 on cardiac functions are yet to be seen in hemodialysis patients. We aimed to evaluate effect of CoQ10 supplementation on diastolic function in a cohort of maintenance hemodialysis patients. This was a prospective, double-blind, placebo-controlled, crossover study in which all patients received placebo and oral CoQ10 200mg/d during the 8 weeks in each phase, with a 4-week washout period. Participants underwent conventional and tissue Doppler echocardiography before and after each study phase. Parameters characterizing left ventricle diastolic function and other standard echocardiographic measurements were recorded. Twenty-eight patients were randomized, but 22 patients completed study protocol. Intraventricular septum (IVS) thickness and left ventricle mass were significantly decreased in CoQ10 group (P = 0.03 and P = 0.01, respectively). Myocardial peak systolic and early diastolic velocities derived from IVS were significantly increased (P = 0.048 and P = 0.04, respectively). Isovolumetric relaxation time and E/Em ratio calculated for IVS also significantly reduced in CoQ10 group (p = 0.02 and p = 0.04, respectively). There was no significant difference in any of the studied echocardiographic parameters in placebo group. The results of this study showed that CoQ10 supplementation did not significantly improved diastolic heart functions compared with placebo in maintenance hemodialysis patients.
KW - Coenzyme Q10
KW - Diastolic heart function
KW - Echocardiography
KW - Hemodialysis
UR - http://www.scopus.com/inward/record.url?scp=84879600702&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879600702&partnerID=8YFLogxK
U2 - 10.1111/hdi.12022
DO - 10.1111/hdi.12022
M3 - Article
C2 - 23360359
AN - SCOPUS:84879600702
VL - 17
SP - 374
EP - 381
JO - Hemodialysis International
JF - Hemodialysis International
SN - 1492-7535
IS - 3
ER -